Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer.

Eyre TA, Collins GP, Gupta A, Coupe N, Sheikh S, Whittaker J, Wang LM, Campo L, Soilleux E, Tysoe F, Cousins R, La Thangue N, Folkes LK, Stratford MRL, Kerr D, Middleton MR.

Cancer. 2019 Jan 1;125(1):99-108. doi: 10.1002/cncr.31791. Epub 2018 Oct 17.

PMID:
30332497
2.

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

Woodcock VK, Clive S, Wilson RH, Coyle VM, Stratford MRL, Folkes LK, Eastell R, Barton C, Jones P, Kazmi-Stokes S, Turner H, Halford S, Harris AL, Middleton MR.

Br J Cancer. 2018 Mar 20;118(6):770-776. doi: 10.1038/bjc.2017.484. Epub 2018 Feb 13.

3.

Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity.

Groselj B, Ruan JL, Scott H, Gorrill J, Nicholson J, Kelly J, Anbalagan S, Thompson J, Stratford MRL, Jevons SJ, Hammond EM, Scudamore CL, Kerr M, Kiltie AE.

Mol Cancer Ther. 2018 Feb;17(2):381-392. doi: 10.1158/1535-7163.MCT-17-0011. Epub 2017 Aug 24.

4.

The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells.

Al-Assar O, Bittner MI, Lunardi S, Stratford MR, McKenna WG, Brunner TB.

Radiother Oncol. 2016 May;119(2):300-5. doi: 10.1016/j.radonc.2016.03.024. Epub 2016 May 28.

PMID:
27247056
5.

Investigation of the anomalous action of 5-hydroxyresorcinol on tyrosinase.

Land EJ, Ramsden CA, Riley PA, Stratford MR.

Pigment Cell Melanoma Res. 2016 Jul;29(4):474-6. doi: 10.1111/pcmr.12490. No abstract available.

PMID:
27166874
6.

Design, synthesis and evaluation of molecularly targeted hypoxia-activated prodrugs.

O'Connor LJ, Cazares-Körner C, Saha J, Evans CN, Stratford MR, Hammond EM, Conway SJ.

Nat Protoc. 2016 Apr;11(4):781-94. doi: 10.1038/nprot.2016.034. Epub 2016 Mar 24.

PMID:
27010756
7.

Oxidative calcium release from catechol.

Riley PA, Stratford MR.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1453-4. doi: 10.1016/j.bmcl.2015.02.036. Epub 2015 Feb 23.

PMID:
25740160
8.

Development of an enzymatic pretargeting strategy for dual-modality imaging.

Knight JC, Mosley M, Stratford MR, Uyeda HT, Benink HA, Cong M, Fan F, Faulkner S, Cornelissen B.

Chem Commun (Camb). 2015 Mar 7;51(19):4055-8. doi: 10.1039/c4cc10265g.

PMID:
25660394
9.

Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.

Wong PP, Demircioglu F, Ghazaly E, Alrawashdeh W, Stratford MR, Scudamore CL, Cereser B, Crnogorac-Jurcevic T, McDonald S, Elia G, Hagemann T, Kocher HM, Hodivala-Dilke KM.

Cancer Cell. 2015 Jan 12;27(1):123-37. doi: 10.1016/j.ccell.2014.10.015.

10.

A novel biosensor for quantitative monitoring of on-target activity of paclitaxel.

Townley HE, Zheng Y, Goldsmith J, Zheng YY, Stratford MR, Dobson PJ, Ahmed AA.

Nanoscale. 2015 Jan 21;7(3):1127-35. doi: 10.1039/c4nr01105h.

PMID:
25483994
11.

Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.

Kerr M, Scott HE, Groselj B, Stratford MR, Karaszi K, Sharma NL, Kiltie AE.

Clin Cancer Res. 2014 Nov 1;20(21):5435-45. doi: 10.1158/1078-0432.CCR-14-0542. Epub 2014 Sep 15.

12.

Cofactor Strap regulates oxidative phosphorylation and mitochondrial p53 activity through ATP synthase.

Maniam S, Coutts AS, Stratford MR, McGouran J, Kessler B, La Thangue NB.

Cell Death Differ. 2015 Jan;22(1):156-63. doi: 10.1038/cdd.2014.135. Epub 2014 Aug 29.

13.

Mechanistic studies of the inactivation of tyrosinase by resorcinol.

Stratford MR, Ramsden CA, Riley PA.

Bioorg Med Chem. 2013 Mar 1;21(5):1166-73. doi: 10.1016/j.bmc.2012.12.031. Epub 2013 Jan 3.

PMID:
23352755
14.

The influence of hydroquinone on tyrosinase kinetics.

Stratford MR, Ramsden CA, Riley PA.

Bioorg Med Chem. 2012 Jul 15;20(14):4364-70. doi: 10.1016/j.bmc.2012.05.041. Epub 2012 May 24.

PMID:
22698780
15.

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection.

Stratford MR, Folkes LK.

J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 1;898:1-6. doi: 10.1016/j.jchromb.2012.03.040. Epub 2012 Apr 24.

PMID:
22578514
16.

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation.

Stratford MR, Folkes LK.

J Pharm Biomed Anal. 2012 Mar 25;62:114-8. doi: 10.1016/j.jpba.2011.12.022. Epub 2011 Dec 24.

PMID:
22251460
17.

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.

Patterson DM, Zweifel M, Middleton MR, Price PM, Folkes LK, Stratford MR, Ross P, Halford S, Peters J, Balkissoon J, Chaplin DJ, Padhani AR, Rustin GJ.

Clin Cancer Res. 2012 Mar 1;18(5):1415-25. doi: 10.1158/1078-0432.CCR-11-2414. Epub 2012 Jan 10.

18.

Modulation of the tumor microvasculature by phosphoinositide-3 kinase inhibition increases doxorubicin delivery in vivo.

Qayum N, Im J, Stratford MR, Bernhard EJ, McKenna WG, Muschel RJ.

Clin Cancer Res. 2012 Jan 1;18(1):161-9. doi: 10.1158/1078-0432.CCR-11-1413. Epub 2011 Nov 7.

19.

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.

Stratford MR, Folkes LK.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Sep 1;879(25):2673-6. doi: 10.1016/j.jchromb.2011.07.014. Epub 2011 Jul 18.

PMID:
21820978
20.

Rapid halogen substitution and dibenzodioxin formation during tyrosinase-catalyzed oxidation of 4-halocatechols.

Stratford MR, Riley PA, Ramsden CA.

Chem Res Toxicol. 2011 Mar 21;24(3):350-6. doi: 10.1021/tx100315n. Epub 2011 Feb 9.

PMID:
21306115
21.

Break-induced ATR and Ddb1-Cul4(Cdt)² ubiquitin ligase-dependent nucleotide synthesis promotes homologous recombination repair in fission yeast.

Moss J, Tinline-Purvis H, Walker CA, Folkes LK, Stratford MR, Hayles J, Hoe KL, Kim DU, Park HO, Kearsey SE, Fleck O, Holmberg C, Nielsen O, Humphrey TC.

Genes Dev. 2010 Dec 1;24(23):2705-16. doi: 10.1101/gad.1970810.

22.

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.

Rustin GJ, Shreeves G, Nathan PD, Gaya A, Ganesan TS, Wang D, Boxall J, Poupard L, Chaplin DJ, Stratford MR, Balkissoon J, Zweifel M.

Br J Cancer. 2010 Apr 27;102(9):1355-60. doi: 10.1038/sj.bjc.6605650. Epub 2010 Apr 13.

23.

Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability.

Pires IM, Bencokova Z, Milani M, Folkes LK, Li JL, Stratford MR, Harris AL, Hammond EM.

Cancer Res. 2010 Feb 1;70(3):925-35. doi: 10.1158/0008-5472.CAN-09-2715. Epub 2010 Jan 26.

24.

In vivo characterization of horseradish peroxidase with indole-3-acetic acid and 5-bromoindole-3-acetic acid for gene therapy of cancer.

Tupper J, Stratford MR, Hill S, Tozer GM, Dachs GU.

Cancer Gene Ther. 2010 Jun;17(6):420-8. doi: 10.1038/cgt.2009.86. Epub 2010 Jan 15.

PMID:
20075982
25.

The influence of catechol structure on the suicide-inactivation of tyrosinase.

Ramsden CA, Stratford MR, Riley PA.

Org Biomol Chem. 2009 Sep 7;7(17):3388-90. doi: 10.1039/b910500j. Epub 2009 Jul 9.

PMID:
19675891
26.

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.

Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, Wellsted D, Taylor NJ, Stirling JJ, Poupard L, Folkes LK, Chan PS, Pedley RB, Chester KA, Owen K, Violet JA, Malaroda A, Green AJ, Buscombe J, Padhani AR, Rustin GJ, Begent RH.

Clin Cancer Res. 2009 Jul 1;15(13):4484-92. doi: 10.1158/1078-0432.CCR-09-0035. Epub 2009 Jun 23.

27.

Evidence consistent with the requirement of cresolase activity for suicide inactivation of tyrosinase.

Land EJ, Ramsden CA, Riley PA, Stratford MR.

Tohoku J Exp Med. 2008 Nov;216(3):231-8.

28.

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis.

Stratford MR.

J Chromatogr A. 2008 Feb 15;1181(1-2):162-5. doi: 10.1016/j.chroma.2007.12.068. Epub 2008 Jan 3.

PMID:
18199444
29.

Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals.

Folkes LK, Christlieb M, Madej E, Stratford MR, Wardman P.

Chem Res Toxicol. 2007 Dec;20(12):1885-94. Epub 2007 Oct 18.

PMID:
17941699
30.

Hypoxia-driven elimination of thiopurines from their nitrobenzyl prodrugs.

Thomson P, Naylor MA, Stratford MR, Lewis G, Hill S, Patel KB, Wardman P, Davis PD.

Bioorg Med Chem Lett. 2007 Aug 1;17(15):4320-2. Epub 2007 May 13.

PMID:
17517505
31.

Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study.

Ng QS, Goh V, Milner J, Stratford MR, Folkes LK, Tozer GM, Saunders MI, Hoskin PJ.

Lancet Oncol. 2007 Feb;8(2):111-8.

PMID:
17267325
32.

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.

Thomson P, Naylor MA, Everett SA, Stratford MR, Lewis G, Hill S, Patel KB, Wardman P, Davis PD.

Mol Cancer Ther. 2006 Nov;5(11):2886-94.

33.

Is sensitization with nicotinamide and carbogen dependent on nicotinamide concentration at the time of irradiation?

Rojas A, Stratford MR, Bentzen SM, Denekamp J.

Int J Radiat Biol. 2004 Jul;80(7):499-506.

PMID:
15360088
34.

ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, Naylor MA, Nolan J, Stratford MR, Chaplin DJ, Hill SA.

Cancer Res. 2002 Dec 15;62(24):7247-53.

35.
36.

Pharmacology and toxicity of nicotinamide combined with domperidone during fractionated radiotherapy.

Bussink J, Stratford MR, van der Kogel AJ, Folkes LK, Kaanders JH.

Radiother Oncol. 2002 Jun;63(3):285-91.

PMID:
12142092
37.

Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release.

Everett SA, Swann E, Naylor MA, Stratford MR, Patel KB, Tian N, Newman RG, Vojnovic B, Moody CJ, Wardman P.

Biochem Pharmacol. 2002 May 1;63(9):1629-39.

PMID:
12007566
38.

5-Fluoroindole-3-acetic acid: a prodrug activated by a peroxidase with potential for use in targeted cancer therapy.

Folkes LK, Greco O, Dachs GU, Stratford MR, Wardman P.

Biochem Pharmacol. 2002 Jan 15;63(2):265-72.

PMID:
11841802
39.

Oxidation of tetrahydrobiopterin by biological radicals and scavenging of the trihydrobiopterin radical by ascorbate.

Patel KB, Stratford MR, Wardman P, Everett SA.

Free Radic Biol Med. 2002 Feb 1;32(3):203-11.

PMID:
11827745
40.

Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.

Kestell P, Zhao L, Jameson MB, Stratford MR, Folkes LK, Baguley BC.

Clin Chim Acta. 2001 Dec;314(1-2):159-66.

PMID:
11718691
41.

Influence of plasma glutathione levels on radiation mucositis.

Wardman P, Folkes LK, Bentzen SM, Stratford MR, Hoskin PJ, Phillips H, Jackson S.

Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):460-4.

PMID:
11583019
42.

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.

Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM.

Anticancer Res. 2001 Jan-Feb;21(1A):93-102.

PMID:
11299795
43.

1-Methylindole-3-carboxaldehyde oxime derivatives.

Janes RW, Potter BS, Naylor MA, Ferguson AC, Patel KB, Stratford MR, Wardman P, Everett SA.

Acta Crystallogr C. 2001 Jan;57(Pt 1):58-61.

PMID:
11173398
44.

Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy.

Korbelik M, Parkins CS, Shibuya H, Cecic I, Stratford MR, Chaplin DJ.

Br J Cancer. 2000 Jun;82(11):1835-43.

45.

Effect of local radiotherapy for bone pain on urinary markers of osteoclast activity.

Hoskin PJ, Stratford MR, Folkes LK, Regan J, Yarnold JR.

Lancet. 2000 Apr 22;355(9213):1428-9.

PMID:
10791529
46.

Bioreductively-activated prodrugs for targeting hypoxic tissues: elimination of aspirin from 2-nitroimidazole derivatives.

Everett SA, Naylor MA, Patel KB, Stratford MR, Wardman P.

Bioorg Med Chem Lett. 1999 May 3;9(9):1267-72.

PMID:
10340612
47.

Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug.

Pettit GR, Rhodes MR, Herald DL, Chaplin DJ, Stratford MR, Hamel E, Pettit RK, Chapuis JC, Oliva D.

Anticancer Drug Des. 1998 Dec;13(8):981-93.

PMID:
10335271
48.

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ.

Cancer Res. 1999 Apr 1;59(7):1626-34.

49.

Determination of combretastatin A-4 and its phosphate ester pro-drug in plasma by high-performance liquid chromatography.

Stratford MR, Dennis MF.

J Chromatogr B Biomed Sci Appl. 1999 Jan 8;721(1):77-85.

PMID:
10027639
50.

Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones.

Jaffar M, Everett SA, Naylor MA, Moore SG, Ulhaq S, Patel KB, Stratford MR, Nolan J, Wardman P, Stratford IJ.

Bioorg Med Chem Lett. 1999 Jan 4;9(1):113-8.

PMID:
9990467

Supplemental Content

Loading ...
Support Center